<DOC>
	<DOC>NCT00975481</DOC>
	<brief_summary>Dimebon will not exhibit abuse potential when compared to placebo or a positive control (alprazolam).</brief_summary>
	<brief_title>A Study To Evaluate The Abuse Potential Of Single Oral Doses Of Dimebon (Latrepirdine) In Healthy Recreational Polydrug Users</brief_title>
	<detailed_description>The main purpose for this study is to determine whether dimebon exhibits abuse potential.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Alprazolam</mesh_term>
	<criteria>Healthy male and/or female subjects between the ages of 18 and 55 years. Recreational polydrug user with a history of CNS depressant use. History of clinically significant neurologic condition(s), such as seizures, convulsions, epilepsy, or significant head injury, as judged by the investigator or designee. A known history of hypersensitivity or previous intolerance to dimebon or other antihistamines. Selfreported history of drug or alcohol dependence (except nicotine or caffeine) in the 2 years prior to screening, or drug or alcohol dependence as defined by the (DSMIVTR) in 12 months prior to screening, including subjects who have ever been in a substance rehabilitation program (other than treatment for smoking cessation). History of clinically significant psychiatric disorder(s), as judged by the investigator or qualified designee.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>oral single-dose 6-way crossover recreational drug users abuse potential pharmacodynamics safety</keyword>
</DOC>